199 related articles for article (PubMed ID: 22543453)
21. Epigenetic lockdown of CDKN1A (p21) and CDKN2A (p16) characterises the neoplastic spindle cell component of giant cell tumours of bone.
Giesche J; Mellert K; Geißler S; Arndt S; Seeling C; von Baer A; Schultheiss M; Marienfeld R; Möller P; Barth TF
J Pathol; 2022 Aug; 257(5):687-696. PubMed ID: 35522566
[TBL] [Abstract][Full Text] [Related]
22. Fine-Needle Aspiration Cytology in Preoperative Diagnosis of Bone Lesions: A Three-Year Study in a Tertiary Care Hospital.
Vangala N; Uppin SG; Pamu PK; Hui M; Nageshwara Rao K; Chandrashekar P
Acta Cytol; 2021; 65(1):75-87. PubMed ID: 33181515
[TBL] [Abstract][Full Text] [Related]
23. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
24. [Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques].
Macagno N; Caselles K; Aubert S; Audard V; Gomez-Brouchet A; Galant C; Guinebretière JM; Karanian M; Larousserie F; Marie B; de Pinieux G; Bouvier C
Ann Pathol; 2018 Apr; 38(2):92-102. PubMed ID: 29580573
[TBL] [Abstract][Full Text] [Related]
25. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
[TBL] [Abstract][Full Text] [Related]
26. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
Dohi O; Ohtani H; Hatori M; Sato E; Hosaka M; Nagura H; Itoi E; Kokubun S
Histopathology; 2009 Oct; 55(4):432-40. PubMed ID: 19817894
[TBL] [Abstract][Full Text] [Related]
27. TGF-beta1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone.
Romeo S; Eyden B; Prins FA; Briaire-de Bruijn IH; Taminiau AH; Hogendoorn PC
J Pathol; 2006 Jan; 208(1):26-34. PubMed ID: 16278817
[TBL] [Abstract][Full Text] [Related]
28. Tumours of bone and their management.
Sweetnam R
Ann R Coll Surg Engl; 1974 Feb; 54(2):63-71. PubMed ID: 4594301
[TBL] [Abstract][Full Text] [Related]
29. [Problems of nomenclature of bone tumors].
Becker W
Z Orthop Ihre Grenzgeb; 1970 Nov; 108(3):476-90. PubMed ID: 4321655
[No Abstract] [Full Text] [Related]
30. [Primary bone tumors and "tumor-like lesions" of the shoulder. Their histopathology and imaging].
Link TM; Brinkschmidt C; Lindner N; Wörtler K; Heindel W
Rofo; 1999 May; 170(5):507-13. PubMed ID: 10370417
[TBL] [Abstract][Full Text] [Related]
31. Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions.
Hui M; Uppin SG; Kumar KK; Radhika S; Chandrasekhar P; Rao KN
Turk Patoloji Derg; 2022; 38(1):9-15. PubMed ID: 34514571
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
Tariq MU; Umer M; Khan Z; Saeed J; Siddiqui MA; Din NU
Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
[TBL] [Abstract][Full Text] [Related]
33. Primary Benign Neoplasms of the Spine.
Ariyaratne S; Jenko N; Iyengar KP; James S; Mehta J; Botchu R
Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37370901
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue.
Perez-Montiel MD; Plaza JA; Dominguez-Malagon H; Suster S
Am J Dermatopathol; 2006 Apr; 28(2):105-11. PubMed ID: 16625070
[TBL] [Abstract][Full Text] [Related]
35. IFITM1, CD10, SMA, and h-caldesmon as a helpful combination in differential diagnosis between endometrial stromal tumor and cellular leiomyoma.
Zhao W; Cui M; Zhang R; Shen X; Xiong X; Ji X; Tao L; Jia W; Pang L; Sun Z; Wang C; Zou H
BMC Cancer; 2021 Sep; 21(1):1047. PubMed ID: 34556086
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow oedema associated with benign and malignant bone tumours.
James SL; Panicek DM; Davies AM
Eur J Radiol; 2008 Jul; 67(1):11-21. PubMed ID: 18358660
[TBL] [Abstract][Full Text] [Related]
37. Chondromyxoid fibroma: a tumor showing myofibroblastic, myochondroblastic, and chondrocytic differentiation.
Nielsen GP; Keel SB; Dickersin GR; Selig MK; Bhan AK; Rosenberg AE
Mod Pathol; 1999 May; 12(5):514-7. PubMed ID: 10349990
[TBL] [Abstract][Full Text] [Related]
38. Role of protein phosphatase in malignant osteogenic and soft tissue tumors.
Sogawa K; Yamada T; Sugita A; Kito K; Tachibana M; Nezu K; Ueda N
Res Commun Mol Pathol Pharmacol; 1996 Jul; 93(1):33-42. PubMed ID: 8865368
[TBL] [Abstract][Full Text] [Related]
39. Benign tumours of the bone: A review.
Hakim DN; Pelly T; Kulendran M; Caris JA
J Bone Oncol; 2015 Jun; 4(2):37-41. PubMed ID: 26579486
[TBL] [Abstract][Full Text] [Related]
40. Tenascin expression in relation to stromal tumour cells in canine gastrointestinal epithelial tumours.
Mukaratirwa S; de Witte E; van Ederen AM; Nederbragt H
J Comp Pathol; 2003; 129(2-3):137-46. PubMed ID: 12921719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
